after enrollment, you will be assigned by chance to one of two groups. one group receives bnt324 and the other receives docetaxel together with prednisone. the assignment is called randomization.

the first dose of the medication assigned to you is given shortly after randomization. bnt324 is given by intravenous infusion at a dose of 6 mg per kilogram of body weight. docetaxel is given by intravenous infusion at a dose of 75 mg per square meter of body‑surface area, and prednisone is taken by mouth at 10 mg each day.

you will return to the clinic for each infusion according to the schedule defined by the study protocol. during each visit, the assigned intravenous medication (bnt324 or docetaxel) is administered over a short period of time.

if you are in the docetaxel group, you will take prednisone 10 mg by mouth every day throughout the treatment period. the tablet is swallowed with water.

at each clinic visit, health care staff will check your vital signs, ask about any side effects, and may draw blood or perform imaging tests to see how the cancer is responding. these checks help determine whether the treatment is safe and effective.

if side effects become severe, the study doctor may lower the dose, pause treatment for a short time, or stop the medication altogether. any change follows the study’s rules for managing adverse events.

treatment continues until one of the following occurs: the cancer shows growth on scans, side effects are unacceptable, or the doctor decides to stop treatment for any other reason. the total length of treatment is not fixed in advance and depends on your individual response.

after the last dose of study medication, you will have follow‑up visits for up to 30 days. during this period, the team will continue to monitor for any late side effects and record any health changes.